Spago Nanomedical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mats Hansen
Chief executive officer
SEK 2.4m
Total compensation
| CEO salary percentage | 72.3% |
| CEO tenure | 10yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.7yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation
Jun 04
We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn
Sep 21We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow
May 26Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven
Mar 30We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely
Feb 03
Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term
Dec 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 34m |
| Jun 30 2024 | n/a | n/a | -SEK 33m |
| Mar 31 2024 | n/a | n/a | -SEK 34m |
| Dec 31 2023 | SEK 2m | SEK 2m | -SEK 42m |
| Sep 30 2023 | n/a | n/a | -SEK 44m |
| Jun 30 2023 | n/a | n/a | -SEK 45m |
| Mar 31 2023 | n/a | n/a | -SEK 45m |
| Dec 31 2022 | SEK 2m | SEK 2m | -SEK 39m |
| Sep 30 2022 | n/a | n/a | -SEK 39m |
| Jun 30 2022 | n/a | n/a | -SEK 41m |
| Mar 31 2022 | n/a | n/a | -SEK 43m |
| Dec 31 2021 | SEK 2m | SEK 1m | -SEK 39m |
| Sep 30 2021 | n/a | n/a | -SEK 32m |
| Jun 30 2021 | n/a | n/a | -SEK 27m |
| Mar 31 2021 | n/a | n/a | -SEK 20m |
| Dec 31 2020 | SEK 2m | SEK 1m | -SEK 19m |
| Sep 30 2020 | n/a | n/a | -SEK 20m |
| Jun 30 2020 | n/a | n/a | -SEK 21m |
| Mar 31 2020 | n/a | n/a | -SEK 21m |
| Dec 31 2019 | SEK 2m | SEK 1m | -SEK 20m |
| Sep 30 2019 | n/a | n/a | -SEK 18m |
| Jun 30 2019 | n/a | n/a | -SEK 15m |
| Mar 31 2019 | n/a | n/a | -SEK 13m |
| Dec 31 2018 | SEK 1m | SEK 1m | -SEK 11m |
Compensation vs Market: Mats's total compensation ($USD215.21K) is about average for companies of similar size in the Swedish market ($USD229.57K).
Compensation vs Earnings: Mats's compensation has increased whilst the company is unprofitable.
CEO
Mats Hansen (53 yo)
10yrs
Tenure
SEK 2,401,000
Compensation
Dr. Mats Hansen, MSc., PhD, serves as the Chief Executive Officer of Spago Nanomedical AB (publ) since 2015. Dr. Hansen has experience from different companies in the life science industry. He served at A...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 10yrs | SEK 2.40m | 0.11% SEK 83.2k | |
| Chief Financial Officer | 6yrs | no data | 0.019% SEK 14.6k | |
| Head of Research & Chief Scientific Officer | no data | no data | 0.048% SEK 36.2k | |
| Chief Development Officer | 3.3yrs | no data | 0.017% SEK 13.0k | |
| Head of CMC & Supply | less than a year | no data | no data |
4.7yrs
Average Tenure
53yo
Average Age
Experienced Management: SPAGO's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | 1.7yrs | SEK 200.00k | 0.14% SEK 107.4k | |
| Medical Advisor | 1.7yrs | SEK 32.00k | no data | |
| Independent Director | 1.7yrs | SEK 100.00k | 0.23% SEK 174.7k | |
| Independent Director | 7yrs | SEK 132.00k | 0.057% SEK 43.2k | |
| Medical Advisor | 2.6yrs | no data | no data | |
| Independent Director | 5.4yrs | SEK 132.00k | 0.021% SEK 15.6k | |
| Medical Advisor | 2.6yrs | no data | no data | |
| Medical Advisor | 1.7yrs | no data | no data | |
| Medical Advisor | 1.6yrs | no data | no data |
1.7yrs
Average Tenure
64yo
Average Age
Experienced Board: SPAGO's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 20:09 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spago Nanomedical AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | Penser Access |
| Johan Unnerus | Redeye |